73 related articles for article (PubMed ID: 9154316)
1. Megakaryocyte pathology and bone marrow fibrosis: the lysyl oxidase connection.
Papadantonakis N; Matsuura S; Ravid K
Blood; 2012 Aug; 120(9):1774-81. PubMed ID: 22767499
[TBL] [Abstract][Full Text] [Related]
2. Single-Cell Analyses Reveal Megakaryocyte-Biased Hematopoiesis in Myelofibrosis and Identify Mutant Clone-Specific Targets.
Psaila B; Wang G; Rodriguez-Meira A; Li R; Heuston EF; Murphy L; Yee D; Hitchcock IS; Sousos N; O'Sullivan J; Anderson S; Senis YA; Weinberg OK; Calicchio ML; ; Iskander D; Royston D; Milojkovic D; Roberts I; Bodine DM; Thongjuea S; Mead AJ
Mol Cell; 2020 May; 78(3):477-492.e8. PubMed ID: 32386542
[TBL] [Abstract][Full Text] [Related]
3. Newly identified roles for PIEZO1 mechanosensor in controlling normal megakaryocyte development and in primary myelofibrosis.
Abbonante V; Karkempetzaki AI; Leon C; Krishnan A; Huang N; Di Buduo CA; Cattaneo D; Ward CM; Matsuura S; Guinard I; Weber J; De Acutis A; Vozzi G; Iurlo A; Ravid K; Balduini A
Am J Hematol; 2024 Mar; 99(3):336-349. PubMed ID: 38165047
[TBL] [Abstract][Full Text] [Related]
4. Megakaryocytes respond during sepsis and display innate immune cell behaviors.
Frydman GH; Ellett F; Jorgensen J; Marand AL; Zukerberg L; Selig MK; Tessier SN; Wong KHK; Olaleye D; Vanderburg CR; Fox JG; Tompkins RG; Irimia D
Front Immunol; 2023; 14():1083339. PubMed ID: 36936945
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of PAK1 generates an ameliorative effect on MPLW515L mouse model of myeloproliferative neoplasms by regulating the differentiation and survival of megakaryocytes.
Fu C; Hu X; Wang S; Yu X; Zhang Q; Zhang L; Qi K; Li Z; Xu K
Exp Hematol; 2023 Nov; 127():59-69.e2. PubMed ID: 37741606
[TBL] [Abstract][Full Text] [Related]
6. Essential thrombocythaemia: a single institution experience of 16 years.
Varghese SJ; Bahey El Din M; Al Hendi M; Kumar R
Indian J Hematol Blood Transfus; 2013 Sep; 29(3):139-46. PubMed ID: 24426359
[TBL] [Abstract][Full Text] [Related]
7. Cellular aging is accelerated in the malignant clone of myeloproliferative neoplasms.
Vieri M; Tharmapalan V; Kalmer M; Baumeister J; Nikolić M; Schnitker M; Kirschner M; Flosdorf N; de Toledo MAS; Zenke M; Koschmieder S; Brümmendorf TH; Beier F; Wagner W
Blood Cancer J; 2023 Nov; 13(1):164. PubMed ID: 37926720
[No Abstract] [Full Text] [Related]
8. Two to tango! IL-13 and TGF-β drive myelofibrosis.
Jutzi JS; Mullally A
Blood; 2022 Dec; 140(26):2767-2768. PubMed ID: 36580345
[No Abstract] [Full Text] [Related]
9.
Lewis MR; Deans TL
bioRxiv; 2023 Mar; ():. PubMed ID: 36909620
[TBL] [Abstract][Full Text] [Related]
10. The Role of Inflammation and Inflammasome in Myeloproliferative Disease.
Longhitano L; Li Volti G; Giallongo C; Spampinato M; Barbagallo I; Di Rosa M; Romano A; Avola R; Tibullo D; Palumbo GA
J Clin Med; 2020 Jul; 9(8):. PubMed ID: 32707883
[TBL] [Abstract][Full Text] [Related]
11. Intravascular large B-cell lymphoma associated with myelofibrosis: A case report.
Choi JG; Cho HH; Kang SR; Jang SM; Yoo EH; Cho HJ; Kim SM; Cho DY
Mol Clin Oncol; 2017 Nov; 7(5):798-802. PubMed ID: 29075489
[TBL] [Abstract][Full Text] [Related]
12. Bone marrow fibrosis in primary myelofibrosis: pathogenic mechanisms and the role of TGF-β.
Agarwal A; Morrone K; Bartenstein M; Zhao ZJ; Verma A; Goel S
Stem Cell Investig; 2016; 3():5. PubMed ID: 27358897
[TBL] [Abstract][Full Text] [Related]
13. [Dysmegakaryocytopoiesis and dysthrombopoiesis in myeloproliferative syndromes].
Brière J; Kiladjian JJ; Peynaud-Debayle E
C R Seances Soc Biol Fil; 1996; 190(5-6):533-9. PubMed ID: 9074718
[TBL] [Abstract][Full Text] [Related]
14. Clonality assays and megakaryocyte culture techniques in essential thrombocythemia.
Yan L; Elkassar N; Gardin C; Briere J
Leuk Lymphoma; 1996 Sep; 22 Suppl 1():31-40. PubMed ID: 8951770
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic criteria of the myeloproliferative disorders (MPD): essential thrombocythaemia, polycythaemia vera and chronic megakaryocytic granulocytic metaplasia.
Michiels JJ
Neth J Med; 1997 Aug; 51(2):57-64. PubMed ID: 9286142
[TBL] [Abstract][Full Text] [Related]
16. Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.
Michiels JJ; Kutti J; Stark P; Bazzan M; Gugliotta L; Marchioli R; Griesshammer M; van Genderen PJ; Brière J; Kiladjian JJ; Barbui T; Finazzi G; Berlin NI; Pearson TC; Green AC; Fruchtmann SM; Silver RT; Hansmann E; Wehmeier A; Lengfelder E; Landolfi R; Kvasnicka HM; Hasselbalch H; Cervantes F; Thiele J
Neth J Med; 1999 Feb; 54(2):46-62. PubMed ID: 10079679
[TBL] [Abstract][Full Text] [Related]
17. Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis (agnogenic myeloid metaplasia).
Michiels JJ; Thiele J
Int J Hematol; 2002 Aug; 76(2):133-45. PubMed ID: 12215011
[TBL] [Abstract][Full Text] [Related]
18. Megakaryocytes and platelets in myeloproliferative disorders.
Briere J; Kiladjian JJ; Peynaud-Debayle E
Baillieres Clin Haematol; 1997 Feb; 10(1):65-88. PubMed ID: 9154316
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
